This proposal represents a request for continued funding of the NIH-sponsored Clinical Pharmacology Fellowship Training Program at the Mayo Clinic-Mayo Clinic College of Medicine-Mayo Medical School. This research training experience is integrated within a broad curriculum that exposes Trainees to critical aspects of the science underlying Clinical Pharmacology ~ all within a supportive, mentoring environment. Clinical Pharmacology represents a "bridge discipline" that is devoted to the study of the interaction between humans and drugs. Within the context of the ongoing" revolution" that is occurring in biomedical science, a revolution that promises to transform medical practice, Clinical Pharmacology lies at the confluence of the disciplines of molecular pharmacology, genomics, proteomics, bioinformatics and rational therapeutics - with an ultimate goal of scientifically "individualized" drug therapy. Therefore, Clinical Pharmacology seeks to enhance our understanding of the molecular basis for drug response and to apply that information at the translational interface to make it possible to tailor drug therapy to both the underlying disease process and the unique characteristics of each individual patient. However, our ability to take advantage of this unique opportunity will require that we train a new generation of Clinical Pharmacologists in science that is based on a foundation provided by the "new biology". Large, comprehensive, integrated academic medical centers like the Mayo Clinic are ideally positioned to train this new generation of Clinical Pharmacologists. Mayo is able to do that because of its long history of integrating basic and clinical medical research, because of a long tradition of contributing to the discipline of Clinical Pharmacology, because the Mayo Clinical Pharmacology Training Program has had decades of experience in successfully recruiting and training physician scientists and because of an historical focus at Mayo on translational science. The Mayo Clinical Pharmacology Fellowship Training Program will continue to emphasize strong laboratory-based research training, systematic exposure to clinical science, and a structured mentorship - with the goal of preparing each Fellow to become a future leader in Clinical Pharmacology.

Agency
National Institute of Health (NIH)
Institute
National Institute of General Medical Sciences (NIGMS)
Type
Institutional National Research Service Award (T32)
Project #
5T32GM008685-15
Application #
8287083
Study Section
Special Emphasis Panel (ZGM1-BRT-5 (PG))
Program Officer
Okita, Richard T
Project Start
1998-07-01
Project End
2013-06-30
Budget Start
2012-07-01
Budget End
2013-06-30
Support Year
15
Fiscal Year
2012
Total Cost
$165,539
Indirect Cost
$20,194
Name
Mayo Clinic, Rochester
Department
Type
DUNS #
006471700
City
Rochester
State
MN
Country
United States
Zip Code
55905
Eugene, Andy R; Masiak, Jolanta (2016) Identifying Treatment Response of Sertraline in a Teenager with Selective Mutism using Electrophysiological Neuroimaging. Int J Clin Pharmacol Toxicol 5:216-219
Elraiyah, Tarig; Jerde, Calvin R; Shrestha, Shikshya et al. (2016) Novel deleterious dihydropyrimidine dehydrogenase variants may contribute to 5-fluorouracil sensitivity in an East African population. Clin Pharmacol Ther :
Pratz, Keith W; Koh, Brian D; Patel, Anand G et al. (2016) Poly (ADP-Ribose) Polymerase Inhibitor Hypersensitivity in Aggressive Myeloproliferative Neoplasms. Clin Cancer Res 22:3894-902
Eugene, Andy R (2016) Metoprolol Dose Equivalence in Adult Men and Women Based on Gender Differences: Pharmacokinetic Modeling and Simulations. Med Sci (Basel) 4:
Eugene, Andy R (2016) Gender based Dosing of Metoprolol in the Elderly using Population Pharmacokinetic Modeling and Simulations. Int J Clin Pharmacol Toxicol 5:209-215
Welch, Brian T; Petersen-Jones, Humphrey G; Eugene, Andy R et al. (2016) Impact of Sleep Disordered Breathing on Carotid Body Size. Respir Physiol Neurobiol :
Eugene, Andy R (2016) The influences of nitric oxide, epinephrine, and dopamine on vascular tone: dose-response modeling and simulations. Hosp Chron 11:1-8
Ding, H; Peterson, K L; Correia, C et al. (2016) Histone deacetylase inhibitors interrupt HSP90 RASGRP1 and HSP90 CRAF interactions to upregulate BIM and circumvent drug resistance in lymphoma cells. Leukemia :
Gupta, Shiv K; Kizilbash, Sani H; Carlson, Brett L et al. (2016) Delineation of MGMT Hypermethylation as a Biomarker for Veliparib-Mediated Temozolomide-Sensitizing Therapy of Glioblastoma. J Natl Cancer Inst 108:
Eugene, Andy R; Nicholson, Wayne T (2015) The Brain and Propranolol Pharmacokinetics in the Elderly. Brain (Bacau) 6:5-14

Showing the most recent 10 out of 49 publications